A Phase 1 Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Ipilimumab (Primary) ; VAC-85135 (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Polycythaemia vera
- Focus Adverse reactions; First in man
- Sponsors Bristol-Myers Squibb; Janssen Research & Development
Most Recent Events
- 04 Apr 2025 Planned primary completion date changed from 20 Feb 2025 to 24 Jun 2025.
- 08 Jan 2025 Planned End Date changed from 27 Nov 2027 to 10 Oct 2025.
- 08 Jan 2025 Planned primary completion date changed from 16 Jan 2026 to 20 Feb 2025.